FDA Almost Ready To Close Door On Rx Versions Of MiraLAX
This article was originally published in The Tan Sheet
Executive Summary
FDA drug center Director Janet Woodcock says the agency “concluded there is no genuine and substantial issues that precludes the withdrawal” of approval of ANDAs for generic Rx polyethylene glycol 3350 products. But FDA is allowing firms with the ANDAs 60 days to again argue their positions.
You may also be interested in...
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.
Some Topical Analgesics Draw Outside US FDA’s Lines For Formulations And Indications
FDA warns six businesses found selling directly to consumers topical formulations containing lidocaine outside the 0.5% to 4% concentration range allowed under OTC monographs for topical analgesics